<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84119">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093949</url>
  </required_header>
  <id_info>
    <org_study_id>SUBSTRATE-HD</org_study_id>
    <nct_id>NCT02093949</nct_id>
  </id_info>
  <brief_title>Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation</brief_title>
  <acronym>SUBSTRATE DH</acronym>
  <official_title>Substrate Ablation Guided by Automatic High Density Mapping for the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate a new AF Substrate mapping method based on automatic high density CFAE detection
      with a multipolar catheter (Pentaray) and the &quot; SCI 30-40 &quot; setting of CARTO CFAE algorithm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Atrial fibrillation termination</measure>
    <time_frame>up to 240 min</time_frame>
    <safety_issue>No</safety_issue>
    <description>patient in sinus rhythm or in atrial tachycardia at the end of the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mapping times in the right and left atria</measure>
    <time_frame>up to 180 min</time_frame>
    <safety_issue>No</safety_issue>
    <description>The mapping times in the right and left atria are measured for each patient  during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time (min)</measure>
    <time_frame>up to 300 min</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LONG TERM RESULTS</measure>
    <time_frame>up to 24 Months post ablation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Atrial Fibrillation recurrence or not  assessed by ECGand/ot 24h-Holter monitoring and clinical examination during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events during and after procedure</measure>
    <time_frame>up to 24 Months post ablation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acquisition points during the procedure</measure>
    <time_frame>up to 180 min</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of total aquisition points (selected by the software algorythm) in the right and left atria for each patient during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency time to terminate Atrial Fibrillation</measure>
    <time_frame>up to 90 mn</time_frame>
    <safety_issue>No</safety_issue>
    <description>during procedure : Radiofrequency time to terminate Atrial Fibrillation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient from 18 à 75, with AF* (paroxysmal, and persistent AF)  and indication of AF
        ablation (including redos)*

        *In accordance with the recommendation of European Society of Cardiology (2010).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient from 18 à 85, with AF* (paroxysmal, and persistent AF)  and indication of AF
             ablation (including redos)* *In accordance with the recommendation of European
             Society of Cardiology (2010).

        Exclusion Criteria:

          -  organized atrial activity (Atrial tachycardia or Flutter)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Seitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Joseph hospital Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien SEITZ, MD</last_name>
    <phone>+330491807044</phone>
    <email>jseitz@hopital-saint-joseph.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence CUREL, MSc</last_name>
    <phone>+330491807044</phone>
    <email>lcurel@hopital-saint-joseph.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence CUREL, mSC</last_name>
      <phone>+33491807044</phone>
      <email>lcurel@hopital-saint-joseph.fr</email>
    </contact>
    <investigator>
      <last_name>Julien seitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume THEODORE, MD</last_name>
      <phone>+334 92 03 85 17</phone>
      <email>gtheodore@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Guillaume Theodore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste de Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clement Bars, MD</last_name>
      <phone>+331 56 61 65 09</phone>
      <email>barsclement@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Clément Bars, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital St. Joseph, Marseille, France</investigator_affiliation>
    <investigator_full_name>SEITZ JULIEN</investigator_full_name>
    <investigator_title>MD , Cardiologist Rythmologist</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
